PhRMA attacks New Mexico’s ‘short on detail’ plan for Canadian drug imports
Industry group PhRMA continues to fight a Trump-era final rule to allow drug imports from Canada as the lobbying group has now petitioned the FDA to reject New Mexico’s import plan because of missing details that may make the imported drugs unsafe and not cost-effective.
The application “provides scant indication that the proposed SIP [Section 804 Importation Program] will lead to any—let alone significant—reduction in cost to consumers,” PhRMA said in its petition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.